Search Word(s)    
Search in   
  Fuzzy Searching 
Sorted by date    Sort by relevance

Tom Lee's Fundstrat Capital Announces May 2026 Rebalance for Granny Shots US Small- & Mid-Cap ETF
15229 bytes   6/9/2026 12:01:33 PM GMT
https://www.tmcnet.com/usubmit/2026/06/09/10396333.htm (10396333)
Sparrow Pharmaceuticals Announces Phase 2a Data Showing Cardiometabolic Benefits of Clofutriben in Adults with Type 2 Diabetes
9739 bytes   6/8/2026 12:30:03 PM GMT
https://www.tmcnet.com/usubmit/2026/06/08/10395609.htm (10395609)
Edesa Biotech Reports Positive Exploratory Data for Paridiprubart in Patients with Acute Kidney Injury
15647 bytes   6/5/2026 1:20:01 PM GMT
https://www.tmcnet.com/usubmit/2026/06/05/10395182.htm (10395182)
Cardiff Oncology Announces Presentation of Positive Results from its Randomized, Controlled Phase 2 Trial of Onvansertib in First-Line RAS-Mutated mCRC at the 2026 ASCO Annual Meeting
17436 bytes   6/2/2026 1:06:01 PM GMT
https://www.tmcnet.com/usubmit/2026/06/02/10392808.htm (10392808)
Actuate Therapeutics Announces ASCO Poster Presentations Demonstrating Compelling Clinical and Biomarker Data for Elraglusib in First-Line Metastatic Pancreatic Cancer
17574 bytes   6/1/2026 11:00:02 AM GMT
https://www.tmcnet.com/usubmit/2026/06/01/10391431.htm (10391431)
Revolution Medicines Announces ASCO Plenary Presentation Highlighting Unprecedented Results from Pivotal Phase 3 RASolute 302 Clinical Trial of Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer
23600 bytes   5/31/2026 12:06:01 PM GMT
https://www.tmcnet.com/usubmit/2026/05/31/10391231.htm (10391231)
Abivax Presents First Quarter 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with Ulcerative Colitis
42402 bytes   5/22/2026 8:05:02 PM GMT
https://www.tmcnet.com/usubmit/2026/05/22/10387972.htm (10387972)
Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints in Patients from Phase 3 Trial of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer Under Prolonged Follow-up at AUA 2026 Annual Meeting
21376 bytes   5/15/2026 8:05:02 PM GMT
https://www.tmcnet.com/usubmit/2026/05/15/10384014.htm (10384014)
PolyPid to Present Data from SHIELD II Phase 3 Trial Demonstrating Reduced Severity of Surgical Site Infection at Surgical Infection Society 2026 Annual Meeting
17323 bytes   4/28/2026 12:30:02 PM GMT
https://www.tmcnet.com/usubmit/2026/04/28/10372467.htm (10372467)
Zimmer Biomet Announces Chief Financial Officer Transition
10800 bytes   4/28/2026 10:29:40 AM GMT
https://www.tmcnet.com/usubmit/2026/04/28/10372226.htm (10372226)

1   2  3  4  5  6  NEXT